7 drugs projected to become blockbusters by 2023

Alia Paavola - Print  | 

Several drugs are slated to make their debuts in 2019, but only seven are projected to achieve blockbuster status within four years, according to a new report from analytic firm Cortellis.

A blockbuster drug is defined as one that reaches $1 billion in annual sales.

Below are the projected blockbusters and their projected 2023 sales:

1. Upadacitinib ($2.2 billion). The drug, manufactured by AbbVie, treats rheumatoid arthritis.

2. Zolgensma ($2.09 billion). The drug is manufactured by AveXiz and Novartis to treat spinal muscular atrophy.

3. Roxadustat ($1.97 billion). The drug treats anemia and is manufactured by AstraZeneca, FibroGen and Astellas.

4. Ultomiris ($1.93 billion). The drug treats Paroxysmal nocturnal hemoglobinuria, a rare blood disease that causes red blood cells to break apart. It is manufactured by Alexion.

5. Skyrizi ($1.74 billion). The drug treats psoriasis. It is manufactured by AbbVie and Boehringer Ingelheim.

6. AR101 ($1.17 billion). The biologic drug, manufactured by Aimmune, is designed to protect patients from severe allergic reactions if they are exposed to peanuts.

7. LentiGlobin ($1.12 billion). The drug, manufactured by Bluebird Bio, treats beta thalassemia, a blood disorder that reduces the production of hemoglobin.

More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy's legal win expected to lower cost of opioid addiction treatment

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.